Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBVax1 malaria transmission-blocking vaccine phase 1 trial
PACTR202201848463189Phase 1Recruiting
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of R0.6C vaccine and Hepatitis B vaccine in malaria (3 arms). Primary endpoint: Safety. Started Feb 2022; status: recruiting.
02
Drugs
R0.6C vaccineHepatitis B vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202201848463189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201848463189.